Anchored versus circulating enzyme therapy to calm psoriasis inflammation
Official title: Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis
Funded at University of Florida · NIH-11262251 · Data updated 2026-11-12
Compares two ways of giving engineered enzyme medicines to help people with psoriasis reduce chronic skin inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | February 2, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $752,222 |
| NIH project number | 5R01AI171045-04 |
| Project ID | NIH-11262251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with active, moderate-to-severe psoriasis and ongoing skin inflammation would be the most likely candidates for this work.
✕Less likely to help
People with mild psoriasis that is well controlled, or those who cannot receive enzyme-based biologic treatments, may be unlikely to benefit directly from this research.
What this research studies
If you have psoriasis, this project compares new engineered enzyme medicines given either anchored to the skin or delivered into the bloodstream. Researchers will examine how these enzymes change immune cell metabolism and behavior so inflammation can move back toward normal. The work begins with lab studies on human cells and tissue models and may guide future treatments for people. The aim is to learn which delivery approach better controls skin inflammation while limiting side effects.
Why it matters
Potential benefit: Could provide a new way to reduce chronic skin inflammation and prevent long-term tissue damage in psoriasis.
How similar studies have gone: Enzyme- and biologic-based therapies have shown promise in preclinical studies and some clinical uses, but tissue-anchored enzyme delivery is a newer and less-tested approach.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Keselowsky, Benjamin George — University of Florida
- Study coordinator: Keselowsky, Benjamin George
Related research
Other NIH-funded projects on the same topics.
-
Testing antiplatelet approaches in psoriasis to improve blood vessel health
A study at NYU School of Medicine will test antiplatelet strategies to reduce heart and blood vessel risk in adults with psoriasis.
-
Topical immunoregulatory therapy for psoriasis
A new topical treatment for psoriasis is being developed to safely reduce skin symptoms and improve quality of life.
-
Understanding psoriasis genetic signals across diverse populations
A study to uncover the genetic factors behind psoriasis in African American people using advanced genomic and epigenetic methods.
-
SerpinB3 and keratinocytes: a new path to understanding psoriasis
This NIH grant explores how a keratinocyte protein called SerpinB3 may drive plaque psoriasis, with the hope of finding new treatments for people with moderate-to-severe disease.
-
Role of a skin protein in psoriasis-related diabetes
A study explores how a skin inflammation signal may contribute to developing type 2 diabetes in people with psoriasis.
-
How satisfied people with plaque psoriasis are with their treatments
This project will try a new questionnaire called DermSat to measure treatment satisfaction among people with plaque psoriasis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.